Evaluating the Revised WORQ in CI Users

NCT ID: NCT04602780

Last Updated: 2020-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

177 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-04

Study Completion Date

2020-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Work Related Questionnaire (WORQ) is a 59-item questionnaire of which each item represents an International Classification of Functioning and disability category. The WORQ was modified and reduced to include only questions relevant to Cochlear Implant (CI) users. In this analysis, a multicentre retrospective review of the revised WORQ in CI users was performed, with the revised WORQ as part of the questionnaires used in the regular clinical follow-up of CI users. Experienced CI users' responses on the questions will be evaluated to define the qualifiers for the revised WORQ.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hearing Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CI users

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over the age of 18 years
* Adults must wear a MED-EL cochlear implant
* Adults may have the following hearing indications and device fitting:

* Unilateral cochlear implant with severe-to-profound hearing loss
* Bilateral cochlear implant with severe-to-profound hearing loss
* Single sided deafness (SSD) where the poorer ear PTA ≥70 dB HL and the better ear PTA ≤30 dB HL with an interaural threshold gap of ≥40 dB HL.
* Asymmetrical hearing loss using a cochlear implant in the poorer ear and a hearing aid in the better ear (also known as bimodal fitting). The poorer ear PTA ≥70 dB HL and the better ear PTA \>30 dB HL and ≤55 dB HL with an interaural threshold gap of ≥15 dB HL.
* Adults should have a minimum of one year's device experience
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

World Hearing Centre

UNKNOWN

Sponsor Role collaborator

Hospital Universitario La Paz

OTHER

Sponsor Role collaborator

Fiona Stanley Hospital

OTHER

Sponsor Role collaborator

Wuerzburg University Hospital

OTHER

Sponsor Role collaborator

University Hospital, Antwerp

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Griet Mertens

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital La Paz

Madrid, , Spain

Site Status

Fiona Stanley Fremantle Hospital Group

Perth, , Australia

Site Status

University Hospital Antwerp

Edegem, , Belgium

Site Status

University Clinic of Würzburg

Würzburg, , Germany

Site Status

World Hearing Centre

Kajetany, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Belgium Germany Poland Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20/23/300

Identifier Type: -

Identifier Source: org_study_id